{
    "url_original": "https://www.wsj.com/articles/johnson-johnson-posts-higher-quarterly-sales-as-it-prepares-for-split-11643115201?mod=business_lead_pos3",
    "url": "johnson-johnson-posts-higher-quarterly-sales-as-it-prepares-for-split-11643115201",
    "title": "Johnson & Johnson Posts Higher Quarterly Sales as It Prepares for Split",
    "sub_head": "Health company, planning to shed its consumer division, had its best quarter yet for Covid-19 vaccine sales",
    "category_1": "Business",
    "category_2": "Earnings",
    "time": "2022-01-25 07:53:00",
    "body": "Johnson & Johnson  finished 2021 with its strongest quarter to date for Covid-19 vaccine sales, contributing to year-over-year revenue growth across the company as it prepares to separate its consumer-health division.<br />In the three months through December, the pharmaceutical and consumer-health company sold $1.62 billion of its Covid-19 vaccine, with international buyers accounting for most of those sales. The quarter brought more than half of J&Jâ€™s total Covid-19 vaccine sales last year."
}